Skip to main content
Journal of Traditional and Complementary Medicine logoLink to Journal of Traditional and Complementary Medicine
. 2019 May 15;10(4):366–377. doi: 10.1016/j.jtcme.2019.05.002

Syzygium aromaticum L.: Traditional herbal medicine against cagA and vacA toxin genes-producing drug resistant Helicobacter pylori

Wagih A El-Shouny b,1, Sameh S Ali a,b,∗∗,1, Hegazy M Hegazy c, Manar K Abd Elnabi b, Asmaa Ali d, Jianzhong Sun a,
PMCID: PMC7365789  PMID: 32695654

Abstract

The Pan-Drug Resistant (PDR), Helicobacter pylori remains an intractable challenge in public health worldwide and this pathogenicity is mainly due to the presence of a cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA). On the other hand, plant extracts such as Syzygium aromaticum contain a diverse array of secondary metabolites, which could be potentially used to combat H. pylori pathogens. To our knowledge, this is the first report on the biomedical potential of S. aromaticum extract against cytotoxin-associated genes producing PDR H. pylori. In this investigation, out of 45 gastric antral biopsy specimens of dyspeptic patients, 20 strains were confirmed as H. pylori. Eight (40%) out of 20 strains were PDR H. pylori while the rest of the strains were Multi-Drug Resistant (MDR) strains. Genotypic analyses of PDR H. pylori strains showed that cagA and vacA genes were found to be 75% and 87.5%, respectively and m2s2 was the most common subtype of vacA gene. S. aromaticum showed a significant higher anti-H. pylori activity compared to that of Cinnamomum zeylanicum and Thymus vulgaris. Eugenol was the major phenolic compound (28.14%) detected in the methanolic extract of S. aromaticum. Clearly, results of the toxicological assessment confirmed the safety of S. aromaticum for use. Hence, these results suggest that S. aromaticum could be a new useful natural antimicrobial agent that could potentially combat cytotoxin genes-producing drug-resistant H. pylori. Moreover, these findings provide a scientific basis for the development of antimicrobial agents from traditional herbal medicines for gastroprotection against gastric ulcer.

Keywords: Helicobacter pylori, Drug resistance, Cytotoxin-associated genes, Syzygium aromaticum, Histopathology, Antibacterial

Graphical abstract

Image 1

Highlights

  • Helicobacter pylori remains an intractable challenge in public health worldwide.

  • CagA and VacA genes are H. pylori pathogenicity dependent.

  • Eight strains of H. pylori were proven to pan-drug resistant.

  • The cagA and vacA genes were found to be 75% and 87.5%, respectively.

  • Syzygium aromaticum extract showed a significant higher anti-H. pylori activity.

1. Introduction

Helicobacter pylori (H. pylori) infection is a well-known risk factor for human gastritis, gastric cancer and inflammation-associated diseases.1, 2, 3 Gastric cancer is a model for inflammation-induced cancer, which is recognized as the third most common cause of cancer related death worldwide.4 H. pylori which has been christened as a class 1 carcinogen by the World Health Organization (WHO), acquired the shape of an epidemic emerging as a principle cause of gastric carcinoma.5 Up to 50% of the world's population harbors H. pylori in the upper gastrointestinal tract and most infected persons are symptomatic.6 On the other hand, the prevalence of H. pylori infection is rising at an alarming rate in developing countries like Egypt and India.7,8

Bacterial virulence factors are often key factors in H. pylori–host interactions pathogenesis, where the risk of ulceration is higher with more virulent strains.9 Between 5 and 10% of H. pylori's 1600 genes are thought to be H. pylori-specific, cytotoxin-associated (CagA) and vacuolating cytotoxin (VacA) are considered the best-described virulence determinants in H. pylori. These two virulence factors are chosen, in this study, as there is considerable evidence regarding their potential roles in disease causation,3 and stimulation of the host inflammatory response.6 CagA, is a highly immunogenic protein encoded at one end of the cag pathogenicity island, which injects CagA and other proteins into host cells.10 Despite the numerous in vitro studies dealing with the identification of a precise role for CagA in the pathogenesis of gastric cancer, its in vivo role remains unidentified.3 In one interesting study, in vivo CagA-expressing H. pylori was associated with an enhanced host inflammatory response and therefore an increased risk of peptic ulcer or gastric cancer.3 CagA-positive H. pylori is also associated with the formation of gastric epithelium cell pedestals, change of the cytoskeleton, and enhancing gastric epithelium cells to produce IL-8.11 The prevalence of CagA among H. pylori varies greatly from almost 100% in East Asia to less than 50% in some western countries.12,13 In comparison with CagA-negative strains, only CagA-positive strains were able to obtain all their necessary nutrients and iron directly from the cells and survive when nutrients were removed from the fluids overlying the cells.3 On the other hand, although almost all H. pylori contain the vacA gene, it remains unclear what the exact role of VacA in disease pathogenesis is.14 However, it is possible that VacA has a major role in disease pathogenesis through the autophagy process where VacA assists in producing vacuoles and H. pylori can survive intracellularly.15 Furthermore, to enhance vacuolation, VacA causes several cellular activities, such as membrane-channel forming, cytochrome c liberates from mitochondria leading to apoptosis and attaches to cell-membrane receptors, followed by induction of a proinflammatory response.16,17 Clearly, the presence of direct H. pylori–host interactions result in genetic instability of the host genome.3,9

Gastric cancer is one of the most prevalent causes of cancer deaths worldwide. Therefore, efforts are underway to eradicate this cancer type based on the elimination of H. pylori.9 Eradication of H. pylori before the development of significant gastric damage, can prevent cancer and the gastric cancer in such cases is known to be an inflammation-associated malignancy.2 It has been reported that, eradication therapy of H. pylori usually consists of a proton pump inhibitor or bismuth compounds in combination with different antibiotics.3,9,18 The conventional antibiotics most widely used for H. pylori therapy include amoxicillin, tetracycline, metronidazole, levofloxacin, clarithromycin and bismuth.3 However, the resistance of H. pylori to the commonly used antibiotics is still increasing worldwide,18 and this resistance has been considered a major reason for therapy failure in the eradication of H. pylori infections, with failure rates of more than 40%.19 The Multi-Drug Resistance (MDR) and Pan-Drug Resistance (PDR) remain an intractable challenge in public health, worldwide.20, 21, 22, 23, 24, 25, 26, 27 MDR strain is defined as resistant to three or more antimicrobial classes. However, resistance to all agents in all antimicrobial classes is defined as PDR.28 These factors, as well as others including the high cost of combination therapy, side effects of therapy and poor compliance of patients have required the search for new alternative therapies, especially from herbs that have lower side effects and can hopefully eradicate this significant human pathogen.

Medicinal plants are a source of natural phytochemical compounds that possess therapeutic properties, and play an important role in treating many human diseases.29, 30, 31, 32 Antibacterial activity of numerous natural products has been recorded against H. pylori.33 For centuries, several types of herbal plants and components derived from natural sources have been used in the treatment of gastric illnesses. Syzygium aromaticum is commonly known as clove and belongs to the family Myrtaceae. Clove has been known to possess various antimicrobial, antioxidant, antiviral, anticancer, anti-inflammatory and anti-nociceptive activities.34, 35, 36 Clove has been used as a food preservative, flavoring agent and for the treatment of gastrointestinal disorders.37 To our knowledge, this is the first report on the biomedical potential of S. aromaticum extract against cytotoxin-associated genes producing PDR H. pylori. The characterization and cytotoxicity activity of S. aromaticum were examined to evaluate the performance of this plant extract as a new leading structure in the biomedical and pharmaceutical fields.

2. Materials and methods

2.1. Processing of gastric biopsy samples

The biopsy specimens were collected from 45 dyspeptic patients who attended the Endoscopic Unit of Tanta University Hospital, after a written approval from these patients who were informed of the final results. Two gastric biopsies were taken from the antrum of each patient. Patients taking antimicrobial drugs, proton pump inhibitor, and/or bismuth salts two weeks prior to the endoscopy were excluded. The first biopsy was placed directly in a sterile tube containing 1 ml of Phosphate Buffer Saline (PBS) solution or added to 1 ml Tryptic Soy Broth (TSB) as a transport medium, then transferred to the Microbiology Unit, Faculty of Science, Tanta University and processed for culture as previously described.38 The second biopsy was used for histopathology examination.

2.2. Isolation and characterization of H. pylori

2.2.1. Phenotypic characterization

Specimens were processed within less than 1 h. Each biopsy specimen from each patient was separately minced within their transport medium in a tissue grinder (mortar) using a sterile pestle and rapidly inoculated onto selective Columbia Blood Agar (CBA; Oxoid, England) plates supplemented with 5% defibrinated sheep blood, including, trimethoprim (5 mg/l), cefsulodin (5 mg/l), vancomycin (10 mg/l), and amphotericin B (5 mg/l). Plates were incubated at 37 °C in an anaerobic jar for 3–10 days under microaerophilic conditions (5% O2, 10% CO2 and 85% N2) by using Campygen kits (Oxoid, Basingstoke, UK). Small fragments from each grinded biopsy specimen were separately placed into Christensen's Urea Broth (CUB) for a rapid urease test.

Bacterial morphology was examined by Gram staining to verify the presence of Gram-negative spiral rod-shaped bacteria and typical colony morphology (small round colonies) as shown in Supplemental data; Fig. S1. Bacterial isolates recovered from microaerophilic conditions were confirmed phenotypically as H. pylori on the basis of positive reactions for urease, catalase and oxidase tests.39 In this study 20 out of 45 cultivated gastric biopsies were positive for H. pylori and were designated as HP-1 to HP-20.

2.2.2. Molecular characterization

Total genomic DNA was extracted from the biopsy homogenates using the Quick- DNA™ Mini prep kit (Zymo Research, USA) following the manufacturer's protocol. The methods applied for determining bacterial genomic DNA concentration, purification, PCR amplification, as well as DNA sequencing were actually performed according to earlier reports.40, 41, 42, 43 Genotypic characterization of H. pylori was carried out by PCR analysis for several bacterial genes including cagA, vacA and 16S rRNA. Primers and PCR amplification conditions used in this study are given in Table 1. The PCR products were confirmed for size and purity on 2% agarose gel run with 1× TAE buffer and stained with ethidium bromide.

Table 1.

Primers and PCR amplification conditions used in this study.

Gene target Orientation Primer sequence (5′-3′) PCR amplification conditions
CagA Forward AATACACCAACGCCTCCA *Initial denaturation: 94 °C for 10 min;
*Denaturation: 35 cycles of heating at 94 °C for 30 s;
*Annealing: 56 °C for 30 s;
*Extension: 72 °C for 50 s;
*Final extension: 72 °C for 10 min.
Reverse ‘TTGTTGCCGCTTTTGCTCTC



VacA (s1/s2) Forward ATGGAAATACAACAAACACAC *Initial denaturation: 94 °C for 10 min;
*Denaturation: 30 cycles of heating at 94 °C for 30 s;
*Annealing: 50 °C for 45 s;
*Extension: 72 °C for 1 min;
*Final extension: 72 °C for 10 min.
Reverse CTGCTTGAATGCGCCAAAC
VacA (m1/m2) Forward CAATCTGTCCAATCAAGCGAG *Initial denaturation: 94 °C for 10 min;
*Denaturation: 35 cycles of heating at 94 °C for 30 s;
*Annealing: 53 °C for 30 s;
*Extension: 72 °C for 2 min;
*Final extension: 72 °C for 10 min.
Reverse GCGTCTAAATAATTCCAAGG



16S rRNA 27F AGAGTTTGATCYTG GCTCAG *Initial denaturation: 95 °C for 5min;
*Denaturation: 35 cycles of heating at 94 °C for 30 s;
*Annealing: 54 °C for 30 s;
*Extension: 72 °C for 3 min;
*Final extension: 72 °C for 10 min.
1513R ACGGYTACCTTGTTACGA

2.3. Histopathologic examination

Histopathology was performed to verify the infection with H. pylori. The gastric biopsies used for histopathology were transported with neutral buffered formalin (10%) for at least 24 h to the Histopathology Laboratory, Faculty of Medicine, Tanta University. These biopsies were then processed.44 The biopsy sections were stained with modified Giemsa stain to determine the presence of H. pylori and for evaluation of the pathological changes to the gastric mucosa.

2.4. Antibiotic susceptibility test

In the present study antibiotic discs of different classes (Oxoid, England) were used to determine the in vitro sensitivity of H. pylori positive clinical strains to ten antimicrobial agents commonly used in the treatment of H. pylori (Table 2). The susceptibility of strains to antibiotics was performed by disk diffusion method.20 The cultivated plates were incubated under microaerophilic conditions for 72 h at 37 °C. The zone of inhibitions was interpreted based on the Clinical and Laboratory Standards Institute (CLSI).45 Out of 20 H. pylori positive clinical strains, eight were proved to be PDR strains.

Table 2.

List of antibiotics used in present study.

Antibiotic Code Class Concentration (μg/disk)
Amoxicillin AX Pencillins 25
Ampicillin AM Pencillins 10
Amoxicillin/clavulanic acid AMC β-lactamase inhibitors 30
Levofloxacin LEV Quinolones 5
Ciprofloxacin CIP Quinolones 5
Metronidazole MTZ Nitroimidazoles 5
Clarithromycin CLR Macrolides 15
Erythromycin ERY Macrolides 15
Tetracycline TE Tetracyclines 30
Gentamicin CN Aminoglycosides 10

2.5. Plant materials

Three herbal plants namely Clove (Syzygium aromaticum L.), Cinnamon (Cinnamomum zeylanicum Nees.) and Thyme (Thymus vulgaris L) (Supplemental data; Table S1) were used in this study and were selected based on research into their use in traditional medicine, and their utilization in popular diets especially in Egypt. The plants were purchased from the local market in Tanta, Egypt. Botanical identification of the plant's samples was performed in the Herbarium, Botany Department, Faculty of Science, Tanta University, Egypt.

2.6. Extract preparation and antibacterial activity

The dried parts of selected plants were ground into powder using a blender. The extraction process was done as previously mentioned.27 Briefly, methanol and ethanol were used as organic solvents for the extraction. Five grams of each powdered herbal plant used in this study were soaked in 40 ml of the solvent for 3–4 days. Remain extracts were filtered and concentrated in a rotatory evaporator at 35 °C. The residual water was removed with a vacuum pump. The weighted crude extracts were suspended in the dimethyl sulfoxide (DMSO) to a final concentration of 50 mg/ml and stored in a refrigerator. As DMSO has no antimicrobial activity, it was used as a negative control. For the preparation of aqueous extracts, the same amount of plant material was soaked in distilled water. The PDR H. pylori strains were screened for their susceptibility to different extracts of the selected plants using the agar well diffusion method.46 Briefly, 100 μl of the fresh culture of H. pylori (106 CFU/ml) was surface inoculated with a sterile cotton swab into Muller-Hinton blood agar (MHBA). The plates lifted to dry for 10 min and wells of 9 mm diameter were made in a MHBA surface using a sterile cork borer. A fixed volume of 100 μl of each extract at 100 mg/ml was placed in the wells. The DiMethyl SulfOxide (DMSO) was taken as a negative control. The experiment was determined in triplicates and results were presented as the mean ± SD. The mean inhibition zone diameters calculated and recorded in millimeters.

2.7. Characterization of the Syzygium aromaticum extract

The methanol extract of S. aromaticum was subjected to Gas Chromatography-Mass Spectrometry (GC-MS) analysis using GC-MS model Claus 580/560S, Perkin Elmer Company. The GC conditions were applied according to Safrudin et al.47 The name, molecular weight and compound nature of the S. aromaticum extract were identified based on the National Institute of Standard and Technology (NIST) library spectra data bases.

Fourier Transform InfraRed (FT-IR) analysis was carried out for determining the characteristic functional groups of the S. aromaticum extract using FT/IR spectrophotometer Perkin-Elmer 1430. The samples were prepared21 and scanned within the transmittance range of 4000-400 cm−1.

2.8. Cytotoxicity assay

Cytotoxicity assay was used to detect the treatment concentration that does not has a toxic effect on normal cells. Peripheral Blood Mononuclear Cells (PBMCs) were selected as normal cell modeling for this experiment. Potential cytotoxicity of the selected S. aromaticum methanol extract was performed48 by using different concentrations of this plant extract (100–1.5 mg/ml). Cell viability was calculated as follows [cell viability % = (controlled cells-treated cells)/controlled cells x 100]. This assay was determined in triplicates and results were presented as the mean ± SD.

2.9. Statistical analysis

In this study, PC-ORD for windows (ver.5) was used for two-way hierarchical cluster analysis using Sorensen methods for distance and beta (−0.025) for group linkage. The data was collected, tabulated and statistically analyzed using Minitab 17.1.0.0 for windows (Minitab Inc., 2013, Pennsylvania, USA). All tests were two-sided. A p-value < 0.05 was considered significant. Data normality was checked for using the Shapiro-Wilk test. An independent t-test was used, and a chi-square test for comparison between two or more groups of categorical data. One-way and two-way ANOVA tests were used to compare between more than two groups.

3. Results and discussion

3.1. Demographic and clinical characteristics of patients

The current study was carried out on 45 dyspeptic patients clinically expected to have an infection caused by H. pylori. The mean age of patients with positive H. pylori was 53 years, which was older than those with a negative H. pylori state but with insignificant statistical difference. The majority of patients were males (31/45; 68.9%) and from rural areas (36/45; 80%) with insignificant statistical association of specific gender type or residence area with positive H. pylori state (Table 3). Even though 40% of positive H. pylori patients were smokers but with insignificant effect, so there is no association between smoking and infection by H. pylori. The endoscopic findings were different in patients (Table 3), the majority (65%) of patients with positive H. pylori showed peptic ulcer (duodenal or gastric), inflammatory mucosa was present in 20% of cases, with insignificant association of peptic ulcer or inflammation with positive H. pylori state. In addition, 20 (44.4%) out of 45 gastric antral biopsy samples were positive for H. pylori culture. Antrum is site of gastric biopsy that used by the majority of endoscopists with highly specificity and sensitivity (up to 90%). Gastric Antral biopsy specimens have been recorded to be more sensitive in H. pylori detection when compared to the specimens of corpus.49

Table 3.

Demographic and clinical characteristics of patients (n = 45).

Traits (n, %) Negative to H. Pylori (n = 25) Positive to H. Pylori (n = 20) P-value
Demography
Age (years) 46.7 ± 12.4 53.1 ± 10.3 0.06a
Gender (male) 16 (64) 15 (75) 0.4b
Residence (Rural) 20 (80) 16 (80) 1.0b
Smoker 13 (52) 8 (40) 0.5b
Endoscopy
Normal 5 (20) 3 (15) 0.4b
Peptic ulcer 10 (40) 13 (65)
Inflammation 10 (40) 4 (20)
Histology
Inflamed mucosa 22 (88) 18 (90) 0.4b
Normal 3 (12) 2 (10)

P-value ≤ 0.05 is considered significant.

a

Independent t-test.

b

Chi square test.

3.2. Histopathologic examination

Positive H. pylori gastric biopsies showed the pathological changes to the gastric mucosa and indicated the presence of H. pylori colonized in the lumen of the gastric glands, with chronic inflammatory infiltrate in lamina propria (Fig. 1A and B). On the other hand, negative H. pylori gastric biopsies showed normal human gastric glands and an absence of H. pylori bacteria from the lumen of the gastric mucosa (Fig. 1 C). The histopathology's advantages include its capability of confirming the infection by H. pylori with high specificity and can explain the degree of inflammation. In this study H. pylori was determined by histopathology in 44.4% of the total cases studied. Inflamed mucosa was the most prominent histological picture of endoscopic biopsy in both positive and negative H. pylori patients, with insignificant association to a particular group of them (Table 3).

Fig. 1.

Fig. 1

Histopathological examination. (A) Inflammatory cells stained by Giemsa stain (400x). The vertical arrow showed ulceration of gastric mucosa (discontinuous of epithelial cells), while horizontal arrows showed atrophic gastric glands and mononuclear cellular infiltration mostly by lymphocytes cells. (B) Positive histopathological result stained by Giemsa stain (1000x). The arrow showed the presence of curved rods H. pylori colonize the lumen of the gastric glands. (C) Negative histopathological result stained by Giemsa stain (400x), showing normal human gastric glands, absence of H. pylori and no inflammatory response.

3.3. Antibiotic susceptibility testing

The clustering analyses of drug resistant-producing H. pylori presented in Fig. 2 revealed that green color clusters, consisting of eight strains; HP-1, HP-5, HP-8, HP-10, HP-12, HP-14, HP-15 and HP-16 showed 100% resistance to the examined antibiotics and were proven to be PDR strains, while the remaining 12 strains (red color clusters) were classified as MDR strains (Fig. 2). The high rate of antibiotic resistance among the isolated H. pylori strains from dyspeptic Egyptian patients is considered a significant finding in this study, where the highest resistance of all 20 H. pylori clinical strains recorded by amoxicillin (AX) and ampicillin (AM) was found to be 100%, followed by metronidazole (MTZ; 95%), clarithromycin (CLR; 90%) and erythromycin (ERY; 90%). Our results are in agreement with Hamada et al.50 who found that 85.7% of H. pylori isolates were resistant to AX, 71.4% of the isolates were resistant to AM, while 57.1% were resistant to ERY. Rasheed et al.51 reported that 54.3% of H. pylori isolates were resistant to AX, while 73.9% and 47.8% of the isolates were resistant to MTZ and ERY, respectively. Goudarzi et al.52 revealed that 27.7% of H. pylori isolates were resistant to AX, while 73.8 and 43.1% of H. pylori isolates were resistant to MTZ and CLR, respectively. In another study, all H. pylori isolates were sensitive to AX, while 61.1 and 22.8% of isolates were resistant to MTZ and CLR, respectively.53 Generally, worldwide rates of H. pylori resistance to AX are considered low and the mechanism of resistance to β-lactam antibiotics in some H. pylori strains is due to a change in the Penicillin Binding Protein (PBP) resulting in a decrease of the affinity of PBP for AX and decreased permeation and accumulation of penicillin into the bacterial cell. Active efflux pumps can also confer resistance to β-lactams.54,55 In contrast, in this study the lowest resistance was recorded by levofloxacin (LEV; 40%), tetracycline (TE; 50%) and ciprofloxacin (CIP; 50%). Eng et al.56 revealed that, 70% of H. pylori isolates were sensitive to LEV and CIP, while none of the isolates showed resistance to TE. Goudarzi et al.52 found that, only 13.4% of H. pylori isolates were resistant to LEV and 29.2% were resistant to TE.

Fig. 2.

Fig. 2

Dendrogram represents clustering analysis of 20 H. Pylori strains (HP-1 to HP-20) based on Drug Resistance (DR). Green cluster (HP-1, HP-5, HP-8, HP-10, HP-12, HP-14, HP-15 and HP-16) represents Pan Drug Resistant (PDR) strains, while red clusters are Multi-Drug Resistant (MDR) strains. CLR, clarithromycin; AMC, amoxicillin/clavulanic acid; MTZ, metronidazole; ERY, erythromycin; CN, gentamicin; TE, tetracycline; LEV, levofloxacin; CIP, ciprofloxacin.

The prevalence of H. pylori antibiotic resistance varies among different geographic regions over the world, but the reported rates in developing nations including Africa are predominantly high.57 Geographic differences linked to the existence of phylogeographic features of H. pylori may be a factor towards explaining the various existing antibiotic resistance.58 As presented in Table 4, the demographic characters of patients with PDR H. pylori showed that, the mean age was 55 years. In addition, 75 and 87.5% were male and from rural areas, respectively. Only 37.5% of them were smokers, with insignificant impact of age, male gender, rural residence or smoking habits on PDR ability of H. pylori (Table 4). Even though the patients who were infected with PDR H. pylori showed inflammatory mucosa and peptic ulcer in an endoscopic picture, 75% of those with MDR H. pylori also showed the same picture with insignificant association of either inflammation nor peptic ulcer with PDR bacteria (Table 4). Also, the patients who were infected with PDR H. pylori showed inflammatory mucosa in the histological picture, and 83.3% of those with MDR H. pylori showed the same picture with insignificant association of inflammation with PDR bacteria (Table 4).

Table 4.

Demographic and clinical characteristics of patients with drug resistant H. pylori (n = 20).

Traits (n, %) Patients with MDR
H. Pylori (n = 12)
Patients with PDR
H. Pylori (n = 8)
P-value
Demography
Age (years) 51.3 ± 11.0 55.8 ± 9.31 0.3a
Gender (male) 9 (75) 6 (75) 1.0b
Residence (Rural) 9 (75) 7 (87.5) 0.4b
Smoker 5 (41.6) 3 (37.5) 0.8b
Endoscopy
Normal 3 (25) 0 (0.0) 0.1b
Peptic ulcer 7 (58.33) 6 (75)
Inflammation 2 (16.67) 2 (25)
Histology
Inflamed mucosa 10 (83.3) 8 (100) 0.4b
Normal 2 (16.7) 0 (0.0)

MDR, Multi-Drug Resistance; PDR, Pan-Drug Resistance.

P-value ≤ 0.05 is considered significant.

a

Independent t-test.

b

Chi square test.

3.4. Genotyping PDR H. pylori strains

Of the 20 isolated H. pylori strains, DNA was purified from 40% H. pylori isolates obtained from eight patients with a positive H. pylori status. Each strain of these PDR strains was genotyped by 16S rRNA (Fig. 3), cagA and vacA (Fig. 4 and Supplemental data; Fig. S2). In this study, the presence of CagA positive strains was in 75% of the PDR H. pylori strains tested. In addition, two strains (HP-12 and HP-15) lacked the cagA gene according to PCR analysis. The presence of CagA positive strains was nearly universal among patients from East Asian countries colonized with H. pylori, and 16/20 of H. pylori isolates (80%) from Vietnamese population were cagA.59 Our results are in accordance with Perez-Perez et al.39 who reported that two patients out of the eight CagA positive H. pylori isolates lacked the cagA gene.

Fig. 3.

Fig. 3

Neighbour-Joining phylogenetic tree showing the placement of the PDR H. pylori strains (HP-1, HP-5, HP-8, HP-10, HP-12, HP-14, HP-15 and HP-16) based on 16S rRNA gene sequencing. GeneBank accession numbers are given in parentheses. The scale bar indicates the numbers of expected substitutions accumulated per site.

Fig. 4.

Fig. 4

Dendrogram profile of the eight PDR H. Pylori strains (HP-1, HP-5, HP-8, HP-10, HP-12, HP-14, HP-15 and HP-16) based on their genotyping characterization and susceptibility to different plant extracts. cagA and vacA, cytotoxin genes; m2s1, m1s1 and m2s2, subtypes of vacA gene; ME, Methanol; ET, Ethanol; AQ, Aqueous; CL, Clove (Syzygium aromaticum); CI, Cinnamon (Cinnamomum zeylanicum); TH, Thyme (Thymus vulgaris).

On the other hand, seven (87.5%) PDR H. pylori strains were vacA positive. Karabiber et al.60 reported that cagE and vacA s1 correlated with CLR and MTZ resistance. Bachir et al.53 revealed that, no statically significant relationship was found between cagA and vacA genotypes and antibiotic resistance except for the MTZ, which had a presence similar to the cagA genotype. In this study, we found that the most common subtype of the vacA gene among PDR H. pylori strains was m2s2 (50%), followed by m1s2 (25%), m2s1 (12.5%), while the subtype m1s2 was not detected in any of the tested PDR strains (Fig. 4). Boukhris et al.61 found that m2s2 was represented the most predominant genotype of vacA gene. Of 20 H. pylori strains, 12 (75%) showed the s1/m2 genotype and four showed the s1/m1 genotype.39 Some of the H. pylori strains showed multiple alleles, despite single colonies being picked.39

As a general rule, all H. pylori strains are considered to be vacA positive. The fact that in this study the HP-10 strain was detected to be vacA negative. These results are in agreement with El-Shenawy et al.62 who found that vacA gene was detected in only 61.6% of H. pylori positive patients, while cagA gene was detected in 26.6%. Similarly, Boukhris et al.61 found that 84.3% of H. pylori positive patients had vacA gene and 59.6% had cagA gene. The variations in frequencies of vacA and cagA genes among H. pylori strains over the world may be due to the genetic heterogeneity and the ability of H. pylori to change the expression of vacA and cagA genes with geographic diversity.63 Various H. pylori genes are more highly diverse in a nucleotide sequence. In addition to variation in the nucleotide sequences of individual genes among H. pylori strains, there is considerable variation in gene content.64 Striking genetic variability at the level of and within single genes has been noted in vacA and cagA genes.65

3.5. Anti- H. pylori activity of different plant extracts

In the current study, ethanol, methanol and aqueous extracts of S. aromaticum, C. zeylanicum and T. vulgaris were screened in vitro for their inhibitory activity against PDR H. pylori strains using the agar well diffusion method (Table 5 and Fig. 5). The results revealed that all the tested plant extracts showed anti-H. pylori activity with an inhibition zone diameter of between zero and 25 ± 0.57 mm while, methanol extracts of these tested plants showed considerable anti- H. pylori activity compared to the ethanol and aqueous extracts. In addition, the DMSO has no antibacterial activity as shown in Fig. 5A. Castillo-Juárez et al.66 found that among 53 different Mexican plant extracts, Moussonia deppeana, Guaiacum coulteri, Annona cherimola, and Persea americana methanol extracts showed the highest anti- H. pylori activity. Lawal et al.67 found that, the methanol extract of Theobroma cacao Linn dried seeds had a potent inhibitory effect against H. pylori clinical strains compared to the n-hexane extract, that did not have any inhibitory activity in-vitro. In contrast, Tabak et al.68 reported that among several plant extracts, ethanol extract of C. zeylanicum and aqueous extract of T. vulgaris had a strong inhibitory effect on H. pylori. Generally, all the different S. aromaticum extracts showed that anti-H. pylori activity was higher than those of C. zeylanicum and T. vulgaris (Table 5). Li et al.69 revealed that among different extracts of 30 Chinese herbal plants, Eugenia caryophyllata ethanol and aqueous extracts showed remarkable inhibitory activity against all test strains of H. pylori. Zaidi et al.70 found that the ethanol extract of S. aromaticum showed anti-inflammatory activity against H. pylori. Whereas, the methanol extract of S. aromaticum showed the highest activity with a mean inhibition zone of 22.87 mm (Fig. 5B). The low activity reported by ethanol and aqueous extracts in this current study may be due to the fact that not enough active constituents were extracted by these solvents.

Table 5.

Antibacterial activity of different plant extracts against the eight PDR H. pyloristrains.

Stain code Inhibition zone diameter (mm)
P$
Syzygium aromaticum (Clove) Cinnamomum zeylanicum (Cinnamon) Thymus vulgaris (Thyme)
Methanol extract
HP-1 24 ± 0.57 21 ± 0.57 19 ± 1.0 0.003
HP-5 23 ± 0.57 20 ± 0.57 18 ± 1.52 0.01
HP-8 25 ± 0.56 23 ± 0.56 20 ± 0.57 < 0.001
HP-10 22 ± 1.0 18 ± 1.0 16 ± 1.0 < 0.001
HP-12 23 ± 1.0 21 ± 1.0 18 ± 1.0 0.01
HP-14 22 ± 0.0 20 ± 0.0 17 ± 0.57 0.001
HP-15 24 ± 1.0 22 ± 1.0 19 ± 0.57 0.003
HP-16 20 ± 0.57 18 ± 1.0 17 ± 0.57 0.002
P$ 0.001 < 0.001 0.013
Ethanol extract
HP-1 22 ± 0.0 19 ± 0.57 18 ± 0.57 0.005
HP-5 21 ± 1.0 20 ± 0.57 17 ± 0.0 0.005
HP-8 24 ± 0.57 22 ± 0.0 20 ± 0.57 0.005
HP-10 20 ± 1.0 18 ± 1.0 16 ± 0.57 0.005
HP-12 18 ± 0.0 20 ± 1.52 17 ± 0.57 0.05
HP-14 21 ± 1.52 19 ± 0.57 16 ± 0.0 0.01
HP-15 22 ± 1.0 20 ± 2.0 18 ± 1.0 0.01
HP-16 18 ± 0.57 16 ± 1.0 15 ± 1.52 0.005
P$ <0.001 0.003 0.001
Aqueous extract
HP-1 15 ± 0.57 13 ± 0.0 15 ± 0.56 0.02
HP-5 16 ± 2.0 11 ± 1.0 13 ± 1.0 0.001
HP-8 18 ± 0.57 15 ± 0.57 16 ± 0.57 0.005
HP-10 15 ± 1.0 13 ± 0.57 14 ± 0.57 0.005
HP-12 13 ± 1.0 0.0 ± 0.0 11 ± 0.57 < 0.001
HP-14 14 ± 0.57 12 ± 1.0 13 ± 1.15 0.005
HP-15 16 ± 0.57 14 ± 0.57 15 ± 0.0 0.02
HP-16 12 ± 1.0 0.0 ± 0.0 0.0 ± 0.0 < 0.001
P$ 0.001 < 0.001 < 0.001

$: Two-way ANOVA, P-value ≤ 0.05 is considered significant.

Fig. 5.

Fig. 5

Anti- H. pylori activity of different plant extracts. (A) Representative blood agar plate showing the effects of Syzygium aromaticum ethanol extract (well no. 1), S. aromaticum methanol extract (well no. 2), negative controls (wells 3 and 4) containing DiMethyl SulfOxide (DMSO) against PDR HP-8 strain. (B) Mean inhibition zone diameters of methanol, ethanol and aqueous plant extracts (Clove, Cinnamon and Thyme).

3.6. Characterization of the Syzygium aromaticum methanol extract from GC-MS and FT-IR analyses

The seven components detected in the S. aromaticum methanol extract by GC-MS analysis are given in Table 6 and Fig. 6. Eugenol (C10H12O2) is the major phenolic compound present in the methanol extract of clove (28.14), followed by eugenol acetate (12.43%) and 4-hydroxy-4-methyl-2-pentanone (5%) (Fig. 6A). The high level of eugenol in the clove is responsible for its strong biological activities.71 Several studies reported antifungal, antibacterial and anti-inflammatory activities of eugenol, which also possessed anti-H. pylori activity.72,73 GC-MS data showed eugenol as the major constituent of clove methanol extract having a molecular ion peak at 164 m/z (Fig. 6B).

Table 6.

Gas chromatography-mass spectrometry (GC-MS) of S. aromaticum methanol extract.

Peak RT (min) Peak area (%) Compound name
2 2.318 1.887 Carophyllene
9 3.054 5.000 4-Hydroxy-4-methyl-2-pentanone
11 10.587 12.430 Eugenol acetate
12 11.052 1.181 Cinnamic acid, p-(trimethylsiloxy)-, methyl ester
13 12.593 28.140 Eugenol
16 21.726 1.363 Sulfurous acid, 2-propyl tridecyl ester
26 27.619 1.552 2-Phenyl-1-(benzimidazolyl) acetic acid

RT, Retention Time.

Fig. 6.

Fig. 6

Syzygium aromaticum (Clove) methanol extract from GC-MS. (A) Chromatogram of S. aromaticum; (B) Mass Spectrum chromatogram of Eugenol.

In this study, FT-IR spectrum of S. aromaticum methanol extract showed a presence of various functional groups (Supplemental data; Fig. S3). The peak appearing at 3372 cm−1 was assigned to stretching vibration of intra molecular H-bonded hydroxyl function, while the peak appearing at 2973 cm−1 was assigned to C–H stretching vibration (alkanes). The peak appearing at 1639 cm−1 was assigned to C Created by potrace 1.16, written by Peter Selinger 2001-2019 C stretching (alkene). The peak appearing at 838 cm−1 was assigned to C–H bending (aromatic), the peaks appearing in the range of 1411–1518 cm−1 were assigned to the presence of C Created by potrace 1.16, written by Peter Selinger 2001-2019 C stretching (aromatic) and the peak appearing at 1038 cm−1 was assigned to various C–O like ethers and phenols. Our results are in agreement with Mohammed et al.74 who used FT-IR to analyze the alcoholic extract of S. aromaticum flowers.

The toxic cyano group (C Created by potrace 1.16, written by Peter Selinger 2001-2019 N: 2220-2260 cm−1) and acetylenic group (C Created by potrace 1.16, written by Peter Selinger 2001-2019 C: 2100-2260 cm−1) are absent as safety indicators of the tested S. aromaticum methanol extract (Supplemental data; Fig. S3). FT-IR was used in previous studies to evaluate the safety of the compounds. El-Zawawy and Ali26 used FT-IR to analyze pyocyanin pigment and its safety was confirmed by the absence of the toxic cyano group and acetylenic group in this pigment. El-Shouny et al.32 used FT-IR to analyze ginger oil and the safety of the oil was also determined by the absence of the toxic cyanide and acetylene groups. Salimon et al.75 analyzed Rubber seed oil by using FT-IR spectroscopy and the results showed that, the toxic cyanide group was absent as an indicator of the safety of this oil. The presence of the hydroxyl group in the S. aromaticum extract might be the reason for its inhibitory effect, this was supported by Ultee et al.76 who reported that, the presence of the hydroxyl group is important for the antimicrobial activity of carvacrol against food-borne pathogen Bacillus cereus. Also, Maddox et al.77 revealed that, the presence of hydroxyl groups in the structure of phenolic acids enhance their inhibitory activity against the phytopathogenic bacterium Xylella fastidiosa.

3.7. Cytotoxicity assay

The results of cytotoxicity (Table 7) showed that the clove methanol extract utilization was safe even up to the maximum concentration (100 mg/ml) that was tested on PBMCs. Clearly, the inhibition rate increases with the increasing of the concentration of the tested S. aromaticum extract, while maximum concentration of clove extract did not reach IC50 of the experiment, and it showed an inhibition rate of 46.73%. These results are in agreement with Hamad et al.50 who studied the cytotoxicity of different herbal extracts and reported that even up to the maximum concentration (20 mg/ml), the extracts did not reach IC50 and showed an inhibition rate of 22.51%.

Table 7.

Cytotoxicity of the S. aromaticum methanol extract.

Extract concentration (mg/ml) Inhibition rate (%)
100 46.73.± 0.15
50 41.93 ± 0.12
25 36.76 ± 0.25
12.5 32.86 ± 0.15
6.25 27.83 ± 0.21
3.125 20.66 ± 0.57
1.5 9.83 ± 0.35
P$ <0.001

$: One way ANOVA, P considered significant if < 0.05.

4. Conclusion

To the best of our knowledge, this study may be the first to investigate the biomedical potential of S. aromaticum extract against cytotoxin-associated genes producing drug-resistant H. pylori. This study has shown that the methanol extract of S. aromaticum exhibited as promising for use in the biomedical application fields, since it allied excellent and significant antibacterial activity against PDR H. pylori. The efficiency of S. aromaticum might be due to the presence of eugenol as the major phenolic compound. Therefore, S. aromaticum methanolic extract may be recommended for treating cytotoxin-associated genes producing PDR, with the potential of enhancing the efficacy for combating drug-resistant strains. This study may serve as a fruitful platform to explore novel derivatives as a new leading structure valued for biomedical therapeutics against H. pylori. In addition, further studies are needed to reveal the gastrointestinal protective mechanism of S. aromaticum.

Conflicts of interest

The authors declare no competing interests.

Acknowledgments

The authors would like to acknowledge the financial support for this study from Egyptian Ministry of Higher Education & Scientific Research (MHESR); Support of Excellent Students Projects (SESP), and from the National Natural Science Foundation of China (NNSF-31772529).

Footnotes

Peer review under responsibility of The Center for Food and Biomolecules, National Taiwan University.

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jtcme.2019.05.002.

Contributor Information

Sameh S. Ali, Email: samh_samir@science.tanta.edu.eg, samh@ujs.edu.cn.

Jianzhong Sun, Email: jzsun1002@ujs.edu.cn.

Appendix A. Supplementary data

The following is the Supplementary data to this article:

Multimedia component 1
mmc1.docx (944.2KB, docx)

References

  • 1.Suzuki K., Tanaka K.S.H., Yano T., et al. Deficiency of stomach-type claudin-18 in mice induces gastric tumor formation independent of H. Pylori infection. Cell Mol Gastroenterol Hepatol. 2019 doi: 10.1016/j.cmgh.2019.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Graham D.Y., Dore M.P. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14(6):577–585. doi: 10.1080/14787210.2016.1178065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Yamaoka Y., Graham D.Y. Helicobacter pylori virulence and cancer pathogenesis. Future Oncol. 2014;10(8):1487–1500. doi: 10.2217/fon.14.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42(2):211–217. doi: 10.1016/j.gtc.2013.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ghosh P., Bodhankar S.L. Determination of risk factors and transmission pathways of Helicobacter pylori in asymptomatic subjects in Western India using polymerase chain reaction. Asian Pac J Trop Dis. 2012:12–17. [Google Scholar]
  • 6.Majumdar D., Bebb J. Helicobacter pylori infection and peptic ulcers. Medicine. 2019;47(5):292–300. [Google Scholar]
  • 7.Suzuki H., Iwasaki E., Hibi T. Helicobacter pylori and gastric cancer. Gastric Cancer. 2009;12(2):79–87. doi: 10.1007/s10120-009-0507-x. [DOI] [PubMed] [Google Scholar]
  • 8.Rana R., Wang S.L., Li J., Wang Y.X., Rao Q.W., Yang C.Q. Helicobacter pylori infection: a recent approach to diagnosis and management. J Biomed. 2017;2(1):45–56. [Google Scholar]
  • 9.Graham D.Y. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Clevel Clin J Med. 2017;84(4):311. doi: 10.3949/ccjm.84a.14110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Tegtmeyer N., Wessler S., Backert S. Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis. FEBS J. 2011;278(8):1190–1202. doi: 10.1111/j.1742-4658.2011.08035.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Boonyanugomol W., Chomvarin C., Hahnvajanawong C., Sripa B., Kaparakis-Liaskos M., Ferrero R.L. Helicobacter pylori cag pathogenicity island (cagPAI) involved in bacterial internalization and IL-8 induced responses via NOD1- and MyD88-dependent mechanisms in human biliary epithelial cells. PLoS One. 2013;8(10) doi: 10.1371/journal.pone.0077358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol. 2010;7(11):629–641. doi: 10.1038/nrgastro.2010.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yamaoka Y., Kodama T., Kashima K., Graham D.Y., Sepulveda A.R. Variants of the 3’ region of the cagA gene in Helicobacter pylori isolates from patients with different H. pylori-associated diseases. J Clin Microbiol. 1998;36(8):2258–2263. doi: 10.1128/jcm.36.8.2258-2263.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Graham D.Y., Lu H., Yamaoka Y. African, Asian or Indian enigma, the East Asian Helicobacter pylori: facts or medical myths. J Dig Dis. 2009;10(2):77–84. doi: 10.1111/j.1751-2980.2009.00368.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Raju D., Hussey S., Ang M., et al. Vacuolating cytotoxin and variants in Atg16L1 that disrupt autophagy promote Helicobacter pylori infection in humans. Gastroenterology. 2012;142(5):1160–1171. doi: 10.1053/j.gastro.2012.01.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Akazawa Y., Isomoto H., Matsushima K., et al. Endoplasmic reticulum stress contributes to Helicobacter pylori VacA-induced apoptosis. PLoS One. 2013;8(12) doi: 10.1371/journal.pone.0082322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Amieva M.R., El-Omar E.M. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology. 2008;134(1):306–323. doi: 10.1053/j.gastro.2007.11.009. [DOI] [PubMed] [Google Scholar]
  • 18.Abadi A.T.B., Yamaoka Y. Helicobacter pylori therapy and clinical perspective. J Glob Antimicrob Resist. 2018;14:111–117. doi: 10.1016/j.jgar.2018.03.005. [DOI] [PubMed] [Google Scholar]
  • 19.Lai C.H., Kuo C.H., Chen P.Y., Poon S.K., Chang C.S., Wang W.C. Association of antibiotic resistance and higher internalization activity in resistant Helicobacter pylori isolates. J Antimicrob Chemother. 2006;57(3):466–471. doi: 10.1093/jac/dki479. [DOI] [PubMed] [Google Scholar]
  • 20.Ali S.S., Morsy R., El-Zawawy N.A., Fareed M.F., Bedaiwy M.Y. Synthesized zinc peroxide nanoparticles (ZnO2-NPs): a novel antimicrobial, anti-elastase, anti-keratinase, and anti-inflammatory approach toward polymicrobial burn wounds. Int J Nanomed. 2017;12:6059–6073. doi: 10.2147/IJN.S141201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Kenawy E., Ali S.S., Al-Etewy M., Sun J., Wu J., El-Zawawy N. Synthesis, characterization and biomedical applications of a novel Schiff base on methyl acrylate-functionalized chitosan bearing p-nitrobenzaldehyde groups. Int J Biol Macromol. 2019;122:833–843. doi: 10.1016/j.ijbiomac.2018.11.005. [DOI] [PubMed] [Google Scholar]
  • 22.Ali S.S., Kenawy E., Sonbol F.I., et al. Pharmaceutical potential of a novel chitosan derivative Schiff base with special reference to antibacterial, anti-Biofilm, antioxidant, anti-Inflammatory, hemocompatibility and cytotoxic activities. Pharm Res. 2019;36(1):5. doi: 10.1007/s11095-018-2535-x. [DOI] [PubMed] [Google Scholar]
  • 23.El-Zawawy N.A., Ali S.S. Pyocyanin as anti-tyrosinase and anti tinea corporis: a novel treatment study. Microb Pathog. 2016;100:213–220. doi: 10.1016/j.micpath.2016.09.013. [DOI] [PubMed] [Google Scholar]
  • 24.Ali S.S., Shaaban M.T., Abomohra A., El-Safity K. Macroalgal activity against multiple drug resistant Aeromonas hydrophila: a novel treatment study towards enhancement of fish growth performance. Microb Pathog. 2016;101:89–95. doi: 10.1016/j.micpath.2016.10.026. [DOI] [PubMed] [Google Scholar]
  • 25.Morsy R., Ali S.S., El-Shetehy M. Development of hydroxyapatite-chitosan gel sunscreen combating clinical multidrug-resistant bacteria. J Mol Struct. 2017;1143:251–258. [Google Scholar]
  • 26.El Zawawy N.A., Ali S.S. Anti-proteolytic activity of Ganoderma lucidum methanol extract against Pseudomonas aeruginosa. J Infect Dev Countr. 2016;10(9):1020–1024. doi: 10.3855/jidc.6929. [DOI] [PubMed] [Google Scholar]
  • 27.El Shafay S.M., Ali S.S., El-Sheekh M.M. Antimicrobial activity of some seaweeds species from Red sea, against multidrug resistant bacteria. Egypt J Aquat Res. 2016;42:65–74. [Google Scholar]
  • 28.Ali S.S., El-Zawawy N.A., Al-Tohamy R., El-Sapagh S., Mustafa A.M., Sun J. Lycium shawii Roem. & Schult.: a new bioactive antimicrobial and antioxidant agent to combat multi-drug/pan-drug resistant pathogens of wound burn infections. J Trad Complement Med. 2019 doi: 10.1016/j.jtcme.2019.01.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Al-Tohamy R., Ali S.S., Saad-Allah K., et al. Phytochemical analysis and assessment of antioxidant and antimicrobial activities of some medicinal plant species from Egyptian flora. J Appl Biomed. 2018;16(4):289–300. [Google Scholar]
  • 30.El-Shouny W.A., Ali S.S., Fayed S.F. The antibacterial activity of Nigella sativa against multidrug resistant Pseudomonas aeruginosa isolated from diabetic wound infections. MATTER: Int J Sci Technol. 2016;2(1):113–134. [Google Scholar]
  • 31.El-Shouny W.A., Ali S.S., Alnabarawy A.M. In vitro antibacterial potential of Rosa Damascena and Terminalia Chebula against bacterial peritonitis. GJBAHS. 2016;5(2):40–49. [Google Scholar]
  • 32.El-Shouny W.A., Ali S.S., Sun J., Samy S.M., Ali A. Drug resistance profile and molecular characterization of extended spectrum beta-lactamase (ESβL)-producing Pseudomonas aeruginosa isolated from burn wound infections. Essential oils and their potential for utilization. Microb Pathog. 2018;116:301–312. doi: 10.1016/j.micpath.2018.02.005. [DOI] [PubMed] [Google Scholar]
  • 33.Nostro A., Cellini L., Bartolomeo S.D., et al. Antibacterial effect of plant extracts against Helicobacter pylori. Phytother Res: J Pharmacol Toxicol. 2005;19(3):198–202. doi: 10.1002/ptr.1640. [DOI] [PubMed] [Google Scholar]
  • 34.Fu Y., Zu Y., Chen L., et al. Antimicrobial activity of clove and rosemary essential oils alone and in combination. Phytother Res. 2007;21(10):989–994. doi: 10.1002/ptr.2179. [DOI] [PubMed] [Google Scholar]
  • 35.Cortés-Rojas D.F., de Souza C.R.F., Oliveira W.P. Clove (Syzygium aromaticum): a precious spice. Asian Pac J Trop Biomed. 2014;4(2):90–96. doi: 10.1016/S2221-1691(14)60215-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Han X., Parker T.L. Anti-inflammatory activity of clove (Eugenia caryophyllata) essential oil in human dermal fibroblasts. Pharm Biol. 2017;55(1):1619–1622. doi: 10.1080/13880209.2017.1314513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Nassan M.A., Mohamed E.H., Abdelhafez S., Ismail T.A. Effect of clove and cinnamon extracts on experimental model of acute hematogenous pyelonephritis in albino rats: immunopathological and antimicrobial study. Int J Immunopathol Pharmacol. 2015;28(1):60–68. doi: 10.1177/0394632015572075. [DOI] [PubMed] [Google Scholar]
  • 38.Peek R.M., Jr., Miller G.G., Tham K.T., Pérez-Pérez G.I., Cover T.L., Atherton J.C. Detection of Helicobacter pylori gene expression in human gastric mucosa. J Clin Microbiol. 1995;33:28–32. doi: 10.1128/jcm.33.1.28-32.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Perez-Perez G.I., Van T.N., Huong D.T., et al. Isolation and characterization of Helicobacter pylori recovered from gastric biopsies under anaerobic conditions. Diagn Microbiol Infect Dis. 2016;86:136–140. doi: 10.1016/j.diagmicrobio.2016.07.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Ali S.S., Abomohra A., Sun J. Effective bio-pretreatment of sawdust waste with a novel microbial consortium for enhanced biomethanation. Bioresour Technol. 2017;238:425–432. doi: 10.1016/j.biortech.2017.03.187. [DOI] [PubMed] [Google Scholar]
  • 41.Ali S.S., Wu J., Xie R., Zhou F., Sun J., Huang M. Screening and characterizing of xylanolytic and xylose-fermenting yeasts isolated from the wood-feeding termite, Reticulitermes chinenesis. PLoS One. 2017;12(7) doi: 10.1371/journal.pone.0181141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ali S.S., Sun J. Effective thermal pretreatment of water hyacinth (Eichhornia crassipes) for the enhancement of biomethanation: VIT® gene probe technology for microbial community analysis with special reference to methanogenic Archaea. J Environ Chem Eng. 2019;7(1):102853. [Google Scholar]
  • 43.Ali S.S., Al-Tohamy R., Sun J., Wu J., Huizi L. Screening and construction of a novel microbial consortium SSA-6 enriched from the gut symbionts of wood-feeding termite, Coptotermes formosanus and its biomass-based biorefineries. Fuel. 2019;236:1128–1145. [Google Scholar]
  • 44.Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis: the updated Sydney system. Am J Surg Pathol. 1996;20(10):1161–1181. doi: 10.1097/00000478-199610000-00001. [DOI] [PubMed] [Google Scholar]
  • 45.Clinical and Laboratory Standard Institute (CLSI) CLSI; Wayne, PA, USA: 2014. Performance Standards for Antimicrobial Susceptibility Testing: 24th Informational Supplement M 100–S24. [Google Scholar]
  • 46.Njume C., Afolayan A.J., Ndip R.N. Preliminary phytochemical screening and in vitro anti-Helicobacter pylori activity of acetone and aqueous extracts of the stem bark of Sclerocarya birrea (Anacardiaceae) Arch Med Res. 2011;42(3):252–257. doi: 10.1016/j.arcmed.2011.04.009. [DOI] [PubMed] [Google Scholar]
  • 47.Safrudin I., Maimulyanti A., Prihadi A.R. Effect of crushing of clove bud (Syzygium aromaticum) and distillation rate on main constituents of the essential oil. Am J Essent Oil Nat Prod. 2015;2(3):12–15. [Google Scholar]
  • 48.EL-Adawi H.I., Khalil M.A., EL-Sheekh M.M., El-Deeb N.M., Hussein M.Z. Cytotoxicity assay and antioxidant activities of the lactic acid bacterial strains. Afr J Microbiol Res. 2012;6(8):1700–1712. [Google Scholar]
  • 49.Dursun M., Yilmaz S., Yukselen V., Kilinç N., Canoruç F., Tuzcu A. Evaluation of optimal gastric mucosal biopsy site and number for identification of Helicobacter pylori, gastric atrophy and intestinal metaplasia. Hepato-Gastroenterology. 2004;51(60):1732–1735. [PubMed] [Google Scholar]
  • 50.Hamad G.M., Taha T.H., El-Deeb N.M., Alshehri A.M. Advanced trends in controlling Helicobacter pylori infections using functional and therapeutically supplements in baby milk. J Food Sci Technol. 2015;52(12):8156–8163. doi: 10.1007/s13197-015-1875-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Rasheed F., Campbell B.J., Alfizah H., et al. Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. Helicobacter. 2014;19(5):387–399. doi: 10.1111/hel.12142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Goudarzi M., Heidary M., Azad M., Fazeli M., Goudarzi H. Evaluation of antimicrobial susceptibility and integron carriage in Helicobacter pylori isolates from patients. Gastroenterol Hepatol Bed Bench. 2016;9(1):S47–S52. [PMC free article] [PubMed] [Google Scholar]
  • 53.Bachir M., Allem R., Tifrit A., et al. Primary antibiotic resistance and its relationship with cagA and vacA genes in Helicobacter pylori isolates from Algerian patients. Braz J Microbiol. 2018;49(3):544–551. doi: 10.1016/j.bjm.2017.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Qureshi N.N., Gallaher B., Schiller N.L. Evolution of amoxicillin resistance of Helicobacter pylori in vitro: characterization of resistance mechanisms. Microb Drug Resist. 2014;20(6):509–516. doi: 10.1089/mdr.2014.0019. [DOI] [PubMed] [Google Scholar]
  • 55.Kwon D.H., Dore M.P., Kim J.J., et al. High-level β-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2003;47(7):2169–2178. doi: 10.1128/AAC.47.7.2169-2178.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Eng N.F., Ybazeta G., Chapman K., et al. Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in northeastern ontario. Can J Infect Dis Med Microbiol. 2015;26(3):137–144. doi: 10.1155/2015/853287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Jaka H., Rhee J.A., Östlundh L., et al. The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis. BMC Infect Dis. 2018;18(1):193. doi: 10.1186/s12879-018-3099-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Wu W., Yang Y., Sun G. Recent insights into antibiotic resistance in Helicobacter pylori eradication. Gastroenterol Res Pract. 2012;2012 doi: 10.1155/2012/723183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Yamaoka Y., Kato M., Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med. 2008;47:1077–1083. doi: 10.2169/internalmedicine.47.0975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Karabiber H., Selimoglu M.A., Otlu B., Yildirim O., Ozer A. Virulence factors and antibiotic resistance in children with Helicobacter pylori gastritis. J Pediatr Gastroenterol Nutr. 2014;58(5):608–612. doi: 10.1097/MPG.0000000000000273. [DOI] [PubMed] [Google Scholar]
  • 61.Boukhris S.A., Amarti A., El Rhazi K., et al. Helicobacter pylori genotypes associated with gastric histo-pathological damages in a Moroccan population. PLoS One. 2013;8(12) doi: 10.1371/journal.pone.0082646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.El-Shenawy A., Diab M., Shemis M., et al. Detection of Helicobacter pylori vacA, cagA and iceA1 virulence genes associated with gastric diseases in Egyptian patients. EJMHG. 2017;18(4):365–371. [Google Scholar]
  • 63.Nejati S., Karkhah A., Darvish H., Validi M., Ebrahimpour S., Nouri H.R. Influence of Helicobacter pylori virulence factors CagA and VacA on pathogenesis of gastrointestinal disorders. Microb Pathog. 2018;117:43–48. doi: 10.1016/j.micpath.2018.02.016. [DOI] [PubMed] [Google Scholar]
  • 64.Cover T.L., Blaser M.J. Helicobacter pylori in health and disease. Gastroenterology. 2009;136(6):1863–1873. doi: 10.1053/j.gastro.2009.01.073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Göttke M.U., Fallone C.A., Barkun A.N., et al. Genetic variability determinants of Helicobacter pylori: influence of clinical background and geographic origin of isolates. J Infect Dis. 2000;181(5):1674–1681. doi: 10.1086/315425. [DOI] [PubMed] [Google Scholar]
  • 66.Castillo-Juárez I., González V., Jaime-Aguilar H., et al. Anti-Helicobacter pylori activity of plants used in Mexican traditional medicine for gastrointestinal disorders. J Ethnopharmacol. 2009;122(2):402–405. doi: 10.1016/j.jep.2008.12.021. [DOI] [PubMed] [Google Scholar]
  • 67.Lawal T.O., Olorunnipa T.A., Adeniyi B.A. Susceptibility testing and bactericidal activities of Theobroma cacao Linn. (cocoa) on Helicobacter pylori in an in vitro study. J Herb Med. 2014;4(4):201–207. [Google Scholar]
  • 68.Tabak M., Armon R., Potasman I., Neeman I. In vitro inhibition of Helicobacter pylori by extracts of thyme. J Appl Microbiol. 1996;80(6):667–672. doi: 10.1111/j.1365-2672.1996.tb03272.x. [DOI] [PubMed] [Google Scholar]
  • 69.Li Y., Xu C., Zhang Q., Liu J.Y., Tan R.X. In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases. J Ethnopharmacol. 2005;98(3):329–333. doi: 10.1016/j.jep.2005.01.020. [DOI] [PubMed] [Google Scholar]
  • 70.Zaidi S.F., Muhammad J.S., Shahryar S., et al. Anti-inflammatory and cytoprotective effects of selected Pakistani medicinal plants in Helicobacter pylori-infected gastric epithelial cells. J Ethnopharmacol. 2012;141(1):403–410. doi: 10.1016/j.jep.2012.03.001. [DOI] [PubMed] [Google Scholar]
  • 71.Gülçin İ. Antioxidant activity of eugenol: a structure–activity relationship study. J Med Food. 2011;14(9):975–985. doi: 10.1089/jmf.2010.0197. [DOI] [PubMed] [Google Scholar]
  • 72.Chaieb K., Hajlaoui H., Zmantar T., et al. The chemical composition and biological activity of clove essential oil, Eugenia caryophyllata (Syzigium aromaticum L. Myrtaceae): a short review. Phytother Res. 2007;21(6):501–506. doi: 10.1002/ptr.2124. [DOI] [PubMed] [Google Scholar]
  • 73.Chami F., Chami N., Bennis S., Trouillas J., Remmal A. Evaluation of carvacrol and eugenol as prophylaxis and treatment of vaginal candidiasis in an immunosuppressed rat model. J Antimicrob Chemother. 2004;54(5):909–914. doi: 10.1093/jac/dkh436. [DOI] [PubMed] [Google Scholar]
  • 74.Mohammed K.A.K., Abdulkadhim H.M., Noori S.I. Chemical composition and anti-bacterial effects of clove (Syzygium aromaticum) flowers. Int J Curr Microbiol App Sci. 2016;5(2):483–489. [Google Scholar]
  • 75.Salimon J., Abdullah B.M., Salih N. Rubber (Hevea brasiliensis) seed oil toxicity effect and Linamarin compound analysis. Lipids Health Dis. 2012;11(1):74. doi: 10.1186/1476-511X-11-74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Ultee A., Bennik M.H.J., Moezelaar R. The phenolic hydroxyl group of carvacrol is essential for action against the food-borne pathogen Bacillus cereus. Appl Environ Microbiol. 2002;68(4):1561–1568. doi: 10.1128/AEM.68.4.1561-1568.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Maddox C.E., Laur L.M., Tian L. Antibacterial activity of phenolic compounds against the phytopathogen Xylella fastidiosa. Curr Microbiol. 2010;60(1):53. doi: 10.1007/s00284-009-9501-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Multimedia component 1
mmc1.docx (944.2KB, docx)

Articles from Journal of Traditional and Complementary Medicine are provided here courtesy of Elsevier

RESOURCES